Required Evidence for Clinical Applications of Liquid Biopsy Using Especially CTCs in Lung CancerTamminga, M. & Groen, H. J. M., Jun-2020, In : Applied Sciences. 10, 11, 9 p., 3704.
Research output: Contribution to journal › Review article › Academic › peer-review
As therapies have become more and more dependent on tumor as well as patient characteristics, obtaining tumor material has become of great importance. Liquid biopsies hold much potential as shown by a large amount of evidence across several studies. Clinical applications for circulating tumor cells (CTCs) are unfortunately still lacking. In part this is due to a lack of studies comparing liquid biopsies to conventional diagnostics and response measurements as well as studies showing that liquid biopsies can be used to switch therapies leading to improved outcomes. However, liquid biopsies using ctDNA for specific markers such as EGFR, ALK, ROS1 or RET have clinical applications because specific drugs are available.
|Number of pages||9|
|Publication status||Published - Jun-2020|
- liquid biopsies, CTC, ctDNA, NSCLC, CIRCULATING TUMOR-CELLS, PROGNOSTIC-SIGNIFICANCE, DIAGNOSTIC BIOMARKER, SURVIVAL, EGFR, CHEMOTHERAPY, PROGRESSION, MUTATIONS, DOCETAXEL, OUTCOMES